Search | IOVS | ARVO Journals

Showing 1 – 20 of 42

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Bevacizumab or Triamcinolone for Persistent Diabetic Macular Edema: 24-week preliminary results

Murilo Wendeborn Rodrigues; Andre Messias; Jose Augusto Cardillo; Rubens C Siqueira; Rodrigo Jorge

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):954.

ARVO Annual Meeting Abstract June 2017

Standardization of retinal thickness and volume on ETDRS grid subdivisions using SD-OCT

Renato Peroni; Rafael Memória; Bruno Nascimento; Lucélia Albieri; Murilo Wendeborn Rodrigues; José Augusto Cardillo; Rodrigo Jorge

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1320.

ARVO Annual Meeting Abstract September 2016

Reduced photoreceptor density over Choroid Nevus

Murilo Wendeborn Rodrigues; Jose A Cardillo; Emil Say; Felipe Borges; Rubens C Siqueira; Rodrigo Jorge

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5099.

ARVO Annual Meeting Abstract June 2015

PASCAL panretinal photocoagulation (PRP) versus ETDRS PRP associated with intravitreal Ranibizumab (IVR) versus only IVR for proliferative diabetic retinopathy treatment

Rafael de Montier Barroso; Andre Messias; Jose A Cardillo; Rodrigo Jorge; Ophthalmology Department, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1773.

ARVO Annual Meeting Abstract June 2015

Reduced-Dose Indocyanine Green Photodynamic Therapy (iPDT) as an Optimized Treatment for Chronic Central Serous Chorioretinopathy

Jose A Cardillo; Leticia Barroso; Murilo Wendeborn Rodrigues; Rodrigo Jorge; Acacio Lima

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):201.

ARVO Annual Meeting Abstract April 2014

The Sympatholytic Non-selective β-blocker PROPRANOLOL as A Non-invasive Therapeutic Approach for the Treatment of Chronic Central Serous Chorioretinopathy (CSC)

Jose A Cardillo; Murilo Wendeborn Rodrigues; Leticia Fernandes Barroso; Rubens C Siqueira; Rodrigo Jorge

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6380.

ARVO Annual Meeting Abstract April 2014

The Potential of Aflibercept as Monotherapy for the Treatment of Refractory or Unresponsive Neovascular Age-Related Macular Degeneration

Murilo Wendeborn Rodrigues; Rodrigo Jorge; Rubens C Siqueira; Jose A Cardillo

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3974.

ARVO Annual Meeting Abstract March 2012

The Potential of Nanolipossomes-Encapsulated Bevacizumab (Avalong) in Prolong VEGF-Inhibition and Enhancing Choroidal Neovascularization -Targeting Following Intravitreal Injection

Jose A. Cardillo; Alessandro J. Dare; Acacio A. Lima Filho; Anselmo G. Oliveira; Rubens Belfort, Jr.

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4637.

ARVO Annual Meeting Abstract March 2012

A Prospective Randomized Trial Of Intravitreal Bevacizumab Versus Ranibizumab For The Management Of Refractory Diabetic Macular Edema

Rodrigo Jorge; Antonio B. Nepomuceno; Erika Takaki; Jefferson A. RIbeiro; Renato Peroni; Ingrid U. Scott; Jose A. Cardillo; Andre Messias

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):347.

ARVO Annual Meeting Abstract March 2012

Gas-Assisted Posterior Vitreous Detachment For The Treatment Of Diabetic Macular Edema

Alessandro J. Dare; Jose A. Cardillo; Rogerio A. Costa; Eduardo Moreira; Francyne Tognin

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):352.

ARVO Annual Meeting Abstract March 2012

Systemic Steroids at the Forefront of New Protocols for the Treatment of Cystoid Macular Edema

Renato Peroni; José A. Cardillo; Frederico T. Souza; Alessandro J. Dare; Rubens Belfort, Jr.

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):905.

Clinical Trials June 2011

Randomized Clinical Trial Evaluating mETDRS versus Normal or High-Density Micropulse Photocoagulation for Diabetic Macular Edema

PDF

Daniel Lavinsky; Jose A. Cardillo; Luiz A. S. Melo, Jr; Alessandro Dare; Michel E. Farah; Rubens Belfort, Jr
TAGS: clinical trials, diabetic macular edema, lasers, light coagulation, visual acuity, burns
Invest. Ophthalmol. Vis. Sci.. 2011; 52(7):4314-4323. https://doi.org/10.1167/iovs.10-6828

ARVO Annual Meeting Abstract April 2011

Aqueous Humor Bioavailability Comparison of Ciprofloxacin 0.3%, Levofloxacin 1.5%. Gatifloxacin 0.3% and Moxifloxacin 0.5% Following a Single Topical Drop Delivery and Intracameral Injection of 0,5% Moxifloxacin and 1% Cefuroxime

Fernando Paganelli; Alessandro J. Dare; José A. Cardillo; Acacio A. Souza-Filho; Renato Peroni; Ansemo G. Oliveira; Antonio C. Pizzolitto; Ana Luisa Hofling-Lima; Rubens Belfort, Jr.

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5693.

ARVO Annual Meeting Abstract April 2011

577 nm Yellow Selective Subthreshold Laser Photocoagulation for the Treatment of Central Serous Chorioretinopathy with Foveal Leakage

Alessandro J. Dare; Jose A. Cardillo; Daniel Lavinsky; Rubens Belfort, Jr.; Carlos E. Moreira

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6622.

ARVO Annual Meeting Abstract April 2011

Restoration Of Retinal Morphology And Residual Scarring After Photocoagulation

Daniel Lavinsky; Thiago Rassi; Jose A. Cardillo; Michel E. Farah; Rubens Belfort, Jr.; Daniel V. Palanker

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):548.

ARVO Annual Meeting Abstract April 2011

A Combined Low Energy, Short Pulsed 577 nm Mild Macular Grid Photocoagulation with 577 nm-Micropulsed Central Laser Stimulation for Diabetic Macular Edema with Foveal Leakage (The Sandwich Grid)

Renato Peroni; Jose A. Cardillo; Alessandro J. Dare; Joao Guilherme Aguirre; Daniel Lavinsky; Michel E. Farah; Rubens Belfort, Jr.

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):590.

ARVO Annual Meeting Abstract April 2011

Treatment Optimization for Short Pulsed and Low Energy Delivery of Pascal Modified Macular Grid Laser Photocoagulation for Diabetic Macular Edema

Jose A. Cardillo; Alessandro J. Dare; Renato Peroni; Joao Guilherme M. Aguirre; Daniel Lavinsky; Michel E. Farah; Rubens Belfort, Jr.

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):591.

ARVO Annual Meeting Abstract April 2011

577 nm Short Pulsed and Low Energy Selective Macular Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

Joao Guilherme M. Aguirre, Sr.; Jose A. Cardillo; Alessandro J. Dare; Renato Peroni; Daniel Lavinsky; Michel E. Farah; Rubens Belfort, Jr.

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):592.

ARVO Annual Meeting Abstract April 2010

Subfoveal Subthreshold Laser Photocoagulation Technique for the Treatment of Central Serous Chorioretinopathy

A. J. Dare; R. Peroni; L. Castro; C. E. Moreira; D. Lavinsky; F. Magalhães; J. A. Cardillo

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):1347.

ARVO Annual Meeting Abstract April 2010

Comparison of a Single Intravitreal Injection of Bevacizumab versus Triamcinolone Acetonide as Primary Treatment for Diffuse Diabetic Macular Edema: The Pan-American Collaborative Retina Study Group (PACORES)

M. Maia; F. M. Penha; L. Wu; J. F. Arevalo; J. A. Cardillo; M. E. Farah; F. J. Rodriguez; M. H. Berrocal; W. C. Furtado; Pan-American Collaborative Retina Study Group (PACORES)

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4225.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Bevacizumab or Triamcinolone for Persistent Diabetic Macular Edema: 24-week preliminary results

Standardization of retinal thickness and volume on ETDRS grid subdivisions using SD-OCT

Reduced photoreceptor density over Choroid Nevus

PASCAL panretinal photocoagulation (PRP) versus ETDRS PRP associated with intravitreal Ranibizumab (IVR) versus only IVR for proliferative diabetic retinopathy treatment

Reduced-Dose Indocyanine Green Photodynamic Therapy (iPDT) as an Optimized Treatment for Chronic Central Serous Chorioretinopathy

The Sympatholytic Non-selective β-blocker PROPRANOLOL as A Non-invasive Therapeutic Approach for the Treatment of Chronic Central Serous Chorioretinopathy (CSC)

The Potential of Aflibercept as Monotherapy for the Treatment of Refractory or Unresponsive Neovascular Age-Related Macular Degeneration

The Potential of Nanolipossomes-Encapsulated Bevacizumab (Avalong) in Prolong VEGF-Inhibition and Enhancing Choroidal Neovascularization -Targeting Following Intravitreal Injection

A Prospective Randomized Trial Of Intravitreal Bevacizumab Versus Ranibizumab For The Management Of Refractory Diabetic Macular Edema

Gas-Assisted Posterior Vitreous Detachment For The Treatment Of Diabetic Macular Edema

Systemic Steroids at the Forefront of New Protocols for the Treatment of Cystoid Macular Edema

Randomized Clinical Trial Evaluating mETDRS versus Normal or High-Density Micropulse Photocoagulation for Diabetic Macular Edema

Aqueous Humor Bioavailability Comparison of Ciprofloxacin 0.3%, Levofloxacin 1.5%. Gatifloxacin 0.3% and Moxifloxacin 0.5% Following a Single Topical Drop Delivery and Intracameral Injection of 0,5% Moxifloxacin and 1% Cefuroxime

577 nm Yellow Selective Subthreshold Laser Photocoagulation for the Treatment of Central Serous Chorioretinopathy with Foveal Leakage

Restoration Of Retinal Morphology And Residual Scarring After Photocoagulation

A Combined Low Energy, Short Pulsed 577 nm Mild Macular Grid Photocoagulation with 577 nm-Micropulsed Central Laser Stimulation for Diabetic Macular Edema with Foveal Leakage (The Sandwich Grid)

Treatment Optimization for Short Pulsed and Low Energy Delivery of Pascal Modified Macular Grid Laser Photocoagulation for Diabetic Macular Edema

577 nm Short Pulsed and Low Energy Selective Macular Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

Subfoveal Subthreshold Laser Photocoagulation Technique for the Treatment of Central Serous Chorioretinopathy

Comparison of a Single Intravitreal Injection of Bevacizumab versus Triamcinolone Acetonide as Primary Treatment for Diffuse Diabetic Macular Edema: The Pan-American Collaborative Retina Study Group (PACORES)

To View More...

You must be signed into an individual account to use this feature.